


## **LISTING OF THE CLAIMS**

1. (Currently Amended) A compound of formula **(I)**:



wherein

$M^1$  is  $-\text{CH}_2-$ ;


$M^2$  is  $-\text{NR}^{24}-$ ;

one of  $R^1$  and  $R^2$  is selected from hydrogen or  $\text{C}_{1-6}$ alkyl and the other is selected from  $\text{C}_{1-6}$ alkyl;

$v$  is 0;

$R^4$  and  $R^7$  are hydrogen;

one of  $R^5$  and  $R^6$  is a group of formula **(IA)**:



and the other of  $R^5$  and  $R^6$  is hydrogen or methylthio;

$Z$  is  $-\text{O}-$ ;

$R^8$  is hydrogen;


$R^9$  is hydrogen;

$R^{10}$  is selected from cyclohexyl, and phenyl optionally substituted by one or more substituents

$R^{28}$ ;

$R^{11}$  is hydrogen;

$R^{13}$  is a group of formula (IB):




wherein:

$R^{14}$  is hydrogen;

$R^{15}$  is hydrogen;

$R^{16}$  is hydroxy;

$R^{17}$  is ethyl substituted on each carbon by one  $R^{47}$ , wherein  $R^{47}$  is hydroxyl, or  $R^{17}$  is a group of formula (IC);



wherein:

$R^{18}$  is hydrogen;

$R^{19}$  is hydrogen;

$R^{20}$  is  $C_{1-10}$ alkyl; wherein  $R^{20}$  may be independently optionally substituted on carbon by one or more  $R^{57}$ ; wherein  $R^{57}$  is selected from halo or hydroxyl;

$p$  is 1;

$q$  is 0;

$r$  is 3;

$m$  is 0;

$n$  is 1;

$z$  is 0-3;

$R^{24}$  is hydrogen; and

each  $R^{28}$  is selected from halo, hydroxy, and  $C_{1-10}$ alkoxy;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester ~~or amide~~ thereof, wherein the hydrolysable ester is selected from the group consisting of:  $\alpha$ -acyloxyalkyl ethers selected from acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy; and *in vivo* hydrolysable ester forming groups for hydroxy selected from alkanoyl, benzoyl, phenylacetyl, alkoxycarbonyl, dialkylcarbamoyl, N-(dialkylaminoethyl)-N-alkylcarbamoyl, dialkylaminoacetyl, and carboxyacetyl.

2. – 5. (Cancelled)


6. (Previously Presented) A compound according to claim 1 wherein one of R<sup>1</sup> and R<sup>2</sup> is C<sub>1-4</sub>alkyl.

7. – 11. (Cancelled)

12. (Currently Amended) A compound having formula: (+/-)-trans-1,1-dioxo-3-ethyl-3-butyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N'-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,4-benzothiazepine, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester ~~or amide~~ thereof, wherein the hydrolysable ester is selected from the group consisting of:  $\alpha$ -acyloxyalkyl ethers selected from acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy; and *in vivo* hydrolysable ester forming groups for hydroxy selected from alkanoyl, benzoyl, phenylacetyl, alkoxycarbonyl, dialkylcarbamoyl, N-(dialkylaminoethyl)-N-alkylcarbamoyl, dialkylaminoacetyl, and carboxyacetyl.


13. (Withdrawn – Previously Presented) A process for preparing a compound of formula **(I)** or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester or amide thereof, as claimed in claim 1, which process comprises of:

*Process 1*): for compounds of formula **(I)**; reacting a compound of formula **(IIa)**:



(IIa)


with a compound of formula (III):



(III)


wherein L is a displaceable group;

Process 2): reacting an acid of formula (IVa):




(IVa)

with an amine of formula (V):




(V);

*Process 3*): for compounds of formula **(I)** wherein  $R^{13}$  is a group of formula **(IB)**; reacting an acid of formula **(VIa)**:




**(VIa)**

with an amine of formula (VI):



**(VI); or**

*Process 4*) for compounds of formula **(I)** wherein  $R^6$  is methylthio ; reacting a compound of formula **(Xb)**:



**(Xb)**

wherein  $L$  is a displaceable group; with a thiol of formula **(XI)**:



wherein R<sup>m</sup> is methylthio;

and optionally:

- i) converting a compound of the formula **(I)** into another compound of the formula **(I)**;
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt or a prodrug.

14. – 17. (Cancelled)

18. (Currently Amended) A pharmaceutical composition which comprises a compound of formula **(I)**, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester ~~or amide~~ prodrug thereof, as ~~claimed~~ in claim 1, in association with a pharmaceutically-acceptable diluent or carrier, wherein the hydrolysable ester is selected from the group consisting of:  $\alpha$ -acyloxyalkyl ethers selected from acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy; and *in vivo* hydrolysable ester forming groups for hydroxy selected from alkanoyl, benzoyl, phenylacetyl, alkoxycarbonyl, dialkylcarbamoyl, N-(dialkylaminoethyl)-N-alkylcarbamoyl, dialkylaminoacetyl, and carboxyacetyl.

19. – 25. (Cancelled)